Presentation of the dose-intensity from an association carboplatin - cyclophosphamide - etoposid for women older than 70 presenting an ovarian carcinoma;Maintien de l'intensité de dose d'une chimiothérapie associant carboplatine, cyclophosphamide et étoposide chez la femme de plus de 70 ans atteinte d'un cancer de l'ovaire

Bulletin du Cancer

Volumn 83, Issue 1, 1996, Pages 63-69

  Delva, R ^a   Mege, M ^a   Gamelin, E ^a   Maillart, P ^a   Lortholary, A ^a   Guerin O ^a   Pein, F ^b   Larra, F ^a  

^a CENTRE PAUL PAPIN   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Dose intensity; Elderly women; Ovarian carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE;

AGE; AGED; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HUMAN; OVARY TUMOR; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; ARTICLE; DRUG DOSE; OVARY CARCINOMA;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0029706906     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. Br Med J 1991;303:884-93
2. Alberts DS, Dahlberg S, Green SJ et al. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. Cancer 1993;71:618-27
3. Barlow JJ, Lele SB. Etoposide (VP 16) plus cisplatin (DDP): a new active chemotherapeutic combination in patients with stage III-IV ovarian adenocarcinoma. J Surg Oncol 1986;32:43
4. Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer 1983;52:1986-92
5. Calvert AH, Newell DR, Grumbell LA et al, Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;17:1748-56
6. Chatelut E, Canal P, Brunner V et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87:573-80
7. Colombo N, Pittelli MR, Parma G, Marzola M, Torri W, Mangioni C. Cisplatin dose intensity in advanced ovarian cancer: a randomized study of conventional dose vs dose-intense cisplatin monochemotherapy. Proc ASCO 1993;11:255
8. Conte PF, Bruzzone M, Gadduci A et al. High doses versus standard doses of cisplatin in combination with epidoxorubicin and cyclophosphamide in advanced ovarian cancer patients with bulky residual disease: a randomized trial. Proc ASCO 1993;11:273
9. Cornelison TL, Reed E. Dose intensity analysis of high-dose carboplatin in refractory ovarian carcinoma relative to age. Cancer 1993;71:650-5
10. De Lena M, Lorusso V, Romito S. Cisplatine plus etoposide as second-line treatment in advanced ovarian carcinoma. Cancer Treat Rep 1986;70:893
11. Edmonson JH, Su J, Krook JE. Treatment of ovarian cancer in elderly women. Cancer 1993;71:615-7
12. Egorin MJ, Van Echo DA, Olman EA et al. Prospective validation of a pharmacologically based dosing scheme for cis-diamminedichloroplalinum (II) analogue diamminecyclobutane dicarboxylatoplatinum. Cancer Res 1985; 45:6502-6
13. Eiermann W, Achterrath W, Lenaz L et al. Carboplatin / etoposide as first line chemotherapy in advanced ovarian cancer. A pilot study. Cancer Chemother Pharmacol 1991;27:389-93
14. Gershenson DM, Follen Mitchell M, Atkinson N et al. Age contrasts in patients with advanced epithelial ovarian cancer: the MD Anderson Cancer Center experience. Cancer 1993;71:638-43
15. Giovanazzi-Bannon S, Rademaker A, Lai G, Benson III A. Treatment tolerance of elderly cancer patients entered into phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol 1994;12:2447-52
16. Gloeckler Ries LA. Ovarian cancer survival and treatment differences by age. Cancer 1993;71:524-9
17. Hacker NF. Controversial aspects of cytoreduction surgery in epithelial ovarian cancer. Clin Obstet Gynecol 1989; 3:49-57
18. Hillcoat BL, Campbell JJ, Pepperell R et al. Phase II trial of VP-16-213 in advanced ovarian carcinoma. Gynecol Oncol 1985;22:162
19. Hoskins WJ, Rubin SC. Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol 1991;18: 213-21
20. Jones A, Wiltshaw E, Harper P et al. A randomized study of high versus conventional dose carboplatin for previously untreated ovarian cancer, Br J Cancer 1992;65 (Suppl XVI):15
21. Levin L, Hryniuk W. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987;5:756-7
22. Mc Guire WP, Hoskins WJ, Brady MF, Homesley HD, Clarke-Pearson DL. A phase III trial of dose-intense versus standard dose cisplatin and cytoxan in advanced ovarian cancer. Proc ASCO 1992;11:226
23. Marc G. Les personnes âgées. Paris: INSEE-Hachette 1990
24. Marchetti DL, Lele SB, Priore RL, McPhee ME, Hreschchyshyn MM. Treatment of advanced ovarian carcinoma in the elderly. Gynecol Oncol 1993;49:86-91
25. Markman M, Lewis JL, Saigo P et al. Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1993;71:634-7
26. NIH. Consensus Conference Statement an Ovarian Cancer. Bethesda (USA): Consensus Development Conferences, NIH, 1994
27. Ozols RF. Cancer épithélial de l'ovaire: données actuelles. Bull Cancer 1993;80,11:955-70
28. Slevin ML, Clark PI, Joe SP et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989;7:1333-40
29. Spencer G. Projections of the population of the United Stales by age, sex, and race, 1988-2020. Washington, DC: US Bureau of the Census, Current Population Reports, 1989. Series P-25, no 1018
30. Thigpen T, Brady MF, Omura GA et al. Age as a prognostic factor in ovarian carcinoma: the Gynecologic Oncology Group experience. Cancer 1993;71:606-14
31. Torri V, Korn FL, Simon R. Dose intensity analysis in advanced ovarian cancer patients. Br J Cancer 1993; 67:190-97
32. US Census Bureau. Decennial census. Washington, DC: Masson NY, US Census Bureau, 1990
33. Voest EE, Van Houwelingen JC, Neijt JP. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives. Eur J Cancer Clin Oncol 1989;4:711-20
34. Walsh SJ, Begg CB, Carbone PP. Cancer chemotherapy in the elderly. Semin Oncol 1989;16:66-75
35. Yancik R. Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1993;71:517-23
36. Yancik R, Ries L. Cancer in the aged: an epidemiologic perspective on treatment issues. Cancer 1991;68(Suppl 11):2502-10